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Cisplatin is an election drug widely used in clinic for the treatment of advanced gastric
cancer. However, the heterogeneity of the gastric tumors and its resistance to the
drugs, make in some cases the response very low and the prognosis unpredictable.
In this manuscript we aim to find the molecular processes involved in cisplatin-induced
apoptosis in two gastric cancer cell lines with different sensitivity to the treatment: AGS
and MKN45. The apoptosis induction is higher in MKN45 than in AGS cells in response
to CDDP. The intrinsic apoptotic pathway study revealed that MKN45 cells undergo
degradation of Mcl-1 together with an increase of Bid and Bad levels, which results in
sensitivity to CDDP. In addition, DNA repair NER pathway is impair in MKN45 cells due
to low levels of XPC and the absence of translocation of XPA and XPD to the nucleus
after stimuli. Altogether, these results suggest that NER and Bcl-2 protein family proteins
are potential targets to improve the response to cisplatin treatment.
Keywords: gastric cancer, apoptosis, cisplatin, NER repair, Bcl-2 family
INTRODUCTION
Gastric cancer (GC) is currently the fourth most diagnosed cancer worldwide (Mandeville et al.,
2009). Despite recent improvements in survival rates, there are still too many patients diagnosed
at advanced stages, for which the current clinical regimen is not efficient. The standard therapy
regimen consists of gastrostomy and adjuvant radio-chemotherapy with cisplatin (CDDP) and
5-Fluorouracil (5FU) treatment (Macdonald et al., 2001; Orth et al., 2014).
Radiation (IR) and chemotherapy cause a variety of DNA lesions, which in turn activate the
DNA damage response (DDR) (Basu and Krishnamurthy, 2010; Orth et al., 2014). Checkpoint
Kinase 1 (Chk1) and Chk2, key effectors in DDR, are multifunctional Ser/Thr kinase proteins,
which represent crucial components of all cell cycle checkpoints (Bartek and Lukas, 2003). They are
Abbreviations: CDDP, cisplatin; DAPI, 4’,6-diamidino-2-phenylindole; ERCC1, excision repair cross-complementation
group 1; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GC, gastric cancer; IF, immunofluorescence; NER, nucleotide
excision repair; PCR, polymerase chain reaction; RT, reverse transcription; XP-A, -C, -D, -G, -F, xeroderma pigmentosum
group A, C, D, G, F.
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both involved in drug resistance and also coordinate the crosstalk
between different checkpoints to ensure genome stability (Chila
et al., 2013; Dillon et al., 2014; Bargiela-Iparraguirre et al.,
2016). For instance, previous in vitro studies from our lab have
demonstrated that in GC, elevated levels of Chk1 and MAD2
confer resistance to radiotherapy and sensitivity to Paclitaxel
(PTX) treatment, respectively (Bargiela-Iparraguirre et al., 2016).
Cisplatin forms upon binding DNA adducts, which lead to
cell death by apoptosis (Ho et al., 2016). CDDP stimulates the
intrinsic apoptotic pathway controlled by the BCL-2 protein
family (Basu and Krishnamurthy, 2010; Maier et al., 2016). This
family includes: the anti-apoptotic subfamily, (Bcl-2, Bcl-XL,
Bcl-w, Mcl-1, BFL1/A-1, and Bcl-B proteins), the pro-apoptotic
subfamily (BAK and BAX), and the BH3-only protein subfamily
(BIM, BID, BIK, BAD, BMF, HRK, PUMA, and NOXA proteins)
(Delbridge et al., 2016). Under stress, the relative expression of
pro- and anti-apoptotic Bcl-2 proteins is modified (Delbridge
and Strasser, 2015). BH3-only Bcl-2 proteins are activated
either transcriptionally or post-transcriptionally leading to
the initiation of apoptosis. DNA damage and growth factor
withdrawal target Mcl-1, which will in turn be degraded by
the ubiquitin-proteasome system and favor apoptosis induction
(Li et al., 2016). Several studies have demonstrated that the
overexpression of Bcl-2 is associated with resistance to cytotoxic
chemotherapeutic agents in patients with GC (Nakata et al., 1998;
Zhuang et al., 2015). The pro-apoptotic protein BAX has been
demonstrated to predict clinical responsiveness to chemotherapy
in patients with GC (Pietrantonio et al., 2012). Other Bcl-2
family members (Bcl-XL, BAK, and Mcl-1) also have a role in
the regulation of chemotherapy-induced apoptosis (Kubo et al.,
2016; Matsumoto et al., 2016). This indicates that proteins from
the Bcl-2 family play a pivotal role in the determination of cell
fate following chemotherapy, through interactions among its
members.
Nucleotide excision repair (NER) is the main pathway
responsible for the removal of bulky lesions induced by CDDP.
The Xeroderma Pigmentosum (XP) complementation group of
proteins XPA–XPG is involved in NER processes including
damage recognition, unwinding, excision, and refilling of DNA
(Spivak, 2015). Of particular importance for NER are the two
helicases subunits XPB and XPD, which are known to open
the DNA helix around the lesion. Then ERCC1 and XPG are
recruited and cleave a fragment of the damaged strand. The final
step is to fill in the gap thanks to a DNA polymerase and a
ligase. The overexpression of some of the components of NER
such as ERCC1 has been directly related to increased resistance
to CDDP in testicular cancer (Usanova et al., 2010). DSBs are
repaired mainly through two pathways, non-homologous end
joining (NHEJ) and homologous recombination (HR). BRCA1,
a tumor suppressor protein involved in several cancers such as
breast cancer, plays a pivotal role in the choice between NHEJ
or HR.
During the development of cancer, tumor cells acquire
different characteristics and therefore, this intrinsic heterogeneity
of the tumor hinders prediction of drug response. We have
previously described CHK1 as a biomarker of response to
radiotherapy in GC (Bargiela-Iparraguirre et al., 2016). In this
manuscript we have compared the process of apoptosis induction
in two gastric adenocarcinoma cell lines (AGS and MKN45),
which show different sensitivity to CDDP. Our data strongly
suggest that MKN45 cells are highly sensitive to CDDP when
compared to AGS cells. When we studied the DNA damage repair
pathway NER in this cell line, our results suggested that NER
activity is impaired in MKN45 cells due to the absence of nuclear
translocation of two key NER proteins (XPA and XPD) and the
lack of XPC expression. Altogether, these results propose new
potential targets that could be used as biomarkers to predict the
response to drugs used in the clinical setting.
MATERIALS AND METHODS
Cell Lines
AGS and MKN45 human gastric adenocarcinoma cell lines were
acquired from ATCC and cultured in F12-Kings and RPMI
medium, respectively (Gibco), and supplemented with FBS 10%.
Cultures were maintained at 37◦C, 5% CO2 and 95% humidity.
AGS and MKN45 cells are wild type for TP53 (Bargiela-
Iparraguirre et al., 2016). Cell lines were authenticated by genetic
profiling using polymorphic short tandem repeat (STRs) loci
[System StemElite ID (Promega)]. The analyzed STRs were
D21S11, TH01, TPOX, vWA, Amelogenine, CSF1PO, D16S539,
D7S820, D13S317, and D5S818. Mycoplasma contamination is
routinely tested in our laboratory.
Chemicals and Plasmid Vectors
Cisplatin was kindly donated from Ferrer FARMA. DAPI was
purchased from Sigma-Aldrich. ATR and ATR-DN expression
plasmids were kindly donated by Dr. P. Muñoz-Cánoves (Vidal
et al., 2005). Crystal violet was purchased from Promega.
Cell Viability
Viability was determined using a crystal violet-based staining
method. Briefly, 5 × 104 cells per well were seeded in 1 ml of
completed medium in 24 multiwell dishes, treated with various
amounts of CDDP solved in sterile water for 72 h and fixed
with 1% glutaraldehyde. After they were washed in 1× PBS, cells
were stained with 0.1% crystal violet. A colorimetric assay using
595 nm Elisa was used to estimate the number of cells per well.
IC50 were calculated by using the GraphPad Prism program. We
used non-linear regression to fit the data to the log (inhibitor) vs.
response (variable slope) curve.
Cell Cycle Analysis
Cells were seeded in 2 ml of completed medium in p60
plates (1.5 × 106 cells per plate) and after appropriate
treatment, adherent and non-adherent cells were harvested and
fixed overnight in 70% ethanol in phosphate-buffered saline
(PBS). For DNA content analysis, the cells were centrifuged
and resuspended in PBS containing 1 µg/ml RNase (Qiagen
Ltd., Crawley, United Kingdom) and 25 µg/ml propidium
iodide, incubated at room temperature for 30 min, and finally
analyzed using a Becton Dickinson Flow Cytometer (Cowley,
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United Kingdom). Data were plotted using Cell Quest Pro
software, with 10,000 events analyzed per sample.
Senescence Assay
A total of 15 × 103 cells were seeded on MW-6 plates in
2 ml of completed medium. Cells were stimulated with CDDP
2.5 µg/ml during 72 h, refreshed with fresh medium and 3 days
later β-galactosidase (SA-β-Gal) activity was quantified using the
Senescence detection kit (BioVision1). Ten areas were counted
with the objective 20× in a microscope Nikon Eclipse TS100 and
ANOVA1 was performed with IBM SPSS 22 software.
Western Blotting
Total protein extracts (WCE) were obtained using the previously
described lysis buffer (Sanchez-Perez et al., 1998). Nuclear and
cytoplasmic cell fractions were obtained as follow: cells were
washed with PBS 1×, centrifuged at 3000 rpm for 4 min at
4◦C and supernatant was discarded. The pellet was resuspended
in cold RBS (20 mM Tris–HCl, pH 7.5, 10 mM NaCl, 3 mM
MgCl2, containing protease, and phosphatase inhibitors) for
10 min and 10% NP40 for 20 min. Next was centrifuged
at 3000 rpm for 4 min at 4◦C, and the supernatant, which
contained the cytoplasmic proteins, was collected. The pellet
was resuspended with cold RBS and 10% NP40, centrifuged
at 3000 rpm for 4 min at 4◦C, washed twice more with
cold RBS, centrifuging between each wash and discarding the
supernatant in each case. The pellet was resuspended in Nuclear
Lysis Buffer (20 mM Tris–HCl, pH 7.5, 0.4 M NaCl, 1 mM
EDTA, containing protease, and phosphatase inhibitors) for
15 min and sonicated for 12 min. Finally, it was centrifuged
at 13200 rpm for 5 min at 4◦C, and the supernatant, which
contained nuclear proteins, was collected. Twenty micrograms
of WCE and 30 µg of nuclear and cytoplasmic fractions per
sample were loaded in 15% (for Bcl2-family), 10% (MAPKs,
XPA, and ERCC1), or 8% (PARP-1, XPC, and XPD), respectively,
SDS-PAGE polyacrylamide gels, and then transferred onto
nitrocellulose membranes, followed by immunodetection using
appropriate antibodies. Antibodies against the following proteins
were: PARP-1 (sc-7150), Mcl-1 (sc-819), DUSP1 (sc-370),
JNK (sc-827), p38 (sc-535), ERK1/2 (sc-154), p-cJun (sc-822),
p-ATF2 (sc-135686), XPA (1:500, sc-28353), XPC (sc-74411),
ERCC1 (sc-10154) and were purchased from Santa Cruz
Technology. The following antibodies were purchased from
Cell Signaling Technology: Cleaved Caspase-3 (Asp175) (#9661),
Bad, Bax, BID, Bak, Bcl-XL (#9942), p62 (#5114), p-p38
(1:2000, #4631), p-ERK1/2 (1:2000, #9106), and XPD (#4636).
The polyclonal antibody for phosphorylated JNK, Rabbit,
(pTPpY) was acquired from Promega Corporation-Spain.
Finally, the FLAG (1:2000) and α-tubulin (1:10000) antibodies
were purchased from Sigma-Aldrich. Unless otherwise specified,
all the above antibodies were used at a working dilution of 1:1000.
RT-PCR
AGS and MKN45 cells were seeded in p60 plates (1.5 × 106
cells per plate in 2 ml of completed medium) and treated
1http://www.biovision.com/
with 10 µg/ml CDDP for different times (0–24 h) and RNA
was isolated as previously described. The relative mRNA level
was calculated by the Ct (2−11Ct) method, using GAPDH
as an endogenous reference and HaCat cells (human normal
keratinocytes cells) as control cells. 11CT represents the
difference between the mean 1CT value of the cells tested and
the mean 1CT value of the calibrator, both calculated after the
same PCR run, in which 1CT is the difference between the CT
of the target mRNA and the CT of the endogenous reference
(GAPDH) of the same sample. The relative quantitative value
was expressed as 2−11Ct. Primer sequences used were previously
described (Chen et al., 2016).
Immunofluorescence
Cells were fixed in formaldehyde for 20 min, washed with PBS
and permeabilized with Triton 0.5% for 10 min, blocked with
BSA 5% for 1 h. Samples were incubated overnight with the
primary antibody at 4◦C, followed by a 1-h incubation with
the adequate secondary antibody at room temperature. DNA
was stained with DAPI. Fluorescence microscopy was performed
using a NIKON Eclipse 90i, and for the image analysis the
software program Nikon NIS-Elements and Image J were used.
The primary antibodies used in our study were Monoclonal
antibody for CDDP-induced Pt(GG) intrastrand adducts in
DNA. Cod: R-C18 from ONCOLYZE; γ-H2AXSer139, purchased
from Millipore, and XPD (1:100; #1284) from Sigma-Aldrich. All
secondary antibodies, conjugated with Alexa Fluor 488, (1:500)
were purchased from Invitrogen. γ-H2AX foci were quantified
with Cell Profiler software and analyzed with IBM SPSS 22 with
two-way ANOVA test.
Comet Assay
We performed the comet assay under alkaline conditions as
described by Landi et al. (1998) and Singh et al. (1988). Briefly,
cells were treated for 3 h with CDDP (10 µg/ml), embedded
in agarose and keep on ice. Before electrophoresis performance,
we introduced single strand breaks by using 2 Gy IR, and
immediately immersed in lysis buffer. This step is done since
the damage induced by CDDP cannot be resolved in alkaline
conditions that allow the electrophoretic migration of the DNA
fragments according to their content in adducts. For the repair
assay, cells were then allowed to recover from the induced
damage thorough washes in PBS and incubation at 37◦C in 5%
fresh media for 30 min, 1, 2, and 3 h. TM was calculated with
ImageJ OpenComet plugin, data were analyzed with IBM SPSS
22 with Kruskal–Wallis and Mann–Whitney tests.
Scoring DNA Damage
Immediately before imaging analysis, slides were stained with
60 µl of a 1 µg/mL ethidium bromide solution for 10 min and
covered with coverslips before imaging using a 20× objective
under a fluorescence microscope (NIKON90i). Experiments were
performed in duplicate. One hundred consecutive cells (50 from
each duplicate slide) were randomly selected (carefully avoiding
the borders of the slides), scored and quantified by ImageJ
analysis software. The extent of the damage was measured
quantitatively by the tail moment (TM), defined as the product
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of the percentage of DNA in the comet tail and the tail length
(Gutierrez-Gonzalez et al., 2013). For the analysis of repair
kinetics, the percentage of residual DNA damage (% RD) at time
t after CDDP was calculated as follows: % RD = 100 × [(DNA
damage at time t after CDDP-DNA damage in control cells before
CDDP)/(DNA damage immediately after CDDP-DNA damage in
control cells before CDDP)] (Marcon et al., 2003).
Cellular Uptake and Distribution by
ICP-MS
To assess the uptake of cisplatin and its intracellular distribution,
AGS and MKN45 cells were seeded in p60 plates in 2 ml of
completed medium (1.5 × 106 cells per plate) and were exposed
to the drug and CDDP content in the nucleus and cytoplasm
was analyzed by ICP-MS. The cells were seed into p60 tissue
culture plates at a density of 1.5 × 106 cells, and allowed to
attach overnight at 37◦C. The adherent cells were incubated
with CDDP 10 µg/ml for 3 h. Then, the cells were washed
with PBS and detached from plates with trypsin. In suspension,
the cells were counted, 106 cells were separated, washed twice
with cold PBS, and centrifuged (1000 rpm, 5 min) to obtain
a pellet. In order to disrupt the cellular membrane, the pellet
was resuspended in lysis buffer (10 mM Tris, 1.5 mM MgCl2,
140 mM NaCl, pH 8.0–8.3) with Nonidet P40 (0.02%). After
15 min incubation on ice, the suspension was centrifuged at
1300 g for 2 min at 4◦C and nuclear fraction (pellet) separated
from the cytoplasmic fraction (supernatant). The Pt content in
the two fractions was measured, after digestion in open vase
with ultrapure HNO3 (65%), H2O2, and HCl, evaporated and
resuspended in ultrapure water to obtain a 2.0% (v/v) nitric acid
solution, by ICP-MS on a ICP-MS NexION 300xx PerkinElmer
instrument, with 187Rhenium used as internal standard. The
protocol was performed at the Elemental analysis unit of UAM
which fulfill the Quality Management System IQNet – ISO
9001:2008.
Statistical Analysis
The Kruskal–Wallis test, a non-parametric procedure was used
to compare responses, as measured by TMs. Repair ability was
measured as the percentage of residual damage at time t which
was calculated as described above. At least 100 nuclei were
measured per condition in IF assays. All data were presented
as mean ± standard deviation (SD) after three independent
experiments. Statistical significance (at p< 0.05) was determined
using Student’s t-test and one-way or two-way ANOVA, using
IBM SPSS 22 software.
RESULTS
Cell Death After Cisplatin Treatment in
Gastric Cancer Cell Lines
We analyzed the viability of AGS and MKN45 cell lines after
treatment with CDDP. Our results showed that survival rate
decreases in a dose dependent manner after CDDP exposure
in both cell lines, being AGS more resistant than MKN45 cells
FIGURE 1 | AGS and MKN45 show different sensitivity to CDDP. (A) Cell
survival percentage of AGS and MKN45 cells after 72 h of CDDP treatment.
Cells were treated with increasing concentrations of CDDP (0–20 µg/ml). The
percentage of viable cells was quantified by the crystal violet method. Data
represent the mean values obtained in three experiments performed in
quadruplicate. (B) Cell cycle profile of AGS and MKN45 cells after 24 h of
CDDP treatment (10 µg/ml). DNA content was assessed by flow cytometry,
and cell cycle distribution was analyzed using Cell Quest Pro software. The
graph shows the percentage of each cell cycle, which is given as the
mean ± standard deviation of three experiments. G2/M, cells in G2 or Mitosis;
S, cells in phase of synthesis of DNA; G1, cells in G1. (C) Cleavage of PARP-1
and Caspase-3 activation were detected by western blot (WB) in cells
harvested at the indicated times after CDDP treatment (10 µg/ml). α-Tubulin
was used as loading control. WB images are representative of the results
obtained in three different experiments made in the same conditions.
(IC50 7.6 µg/ml vs. IC50 2 µg/ml, respectively) (Figure 1A),
and at different times of exposure (Supplementary Figure 1).
Then we studied the cell cycle profile and the results showed
that the percentage of apoptotic AGS cells is 6.34%, in contrast
to the 28.38% of apoptotic MKN45 cells (Figure 1B). Based
on these data, we looked at specific biochemical markers
such as caspase-3 activation and PARP cleavage after equitoxic
CDDP treatment. The western blot analysis of MKN45 cells
showed PARP and caspase-3 cleavage, indicating proteolysis
and activation, respectively. In contrast, CDDP fails to activate
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caspase-3 and PARP proteolysis in AGS cells (Figure 1C),
and this result suggests a different apoptosis induction in
both cell lines. Rationally, we checked out additional pathways
that could be involved in cell death, such us senescence
and autophagy. In order to study senescence, we analyzed
SA-β-galactosidase activity in AGS and MKN45 cells treated with
CDDP (Supplementary Figure 2A). Our results showed similar
induction of senescence in both cell lines. To analyze autophagy,
we use western blot analysis of p62 (one of the most significant
markers in autophagy). The p62 expression in GC cells is similar
in both cell lines revealing p62 degradation (Supplementary
Figure 2B). The different viability caused by CDDP in AGS and
MKN45 cells could be produce by a different apoptosis activation.
Intrinsic Apoptosis Pathway Mediated by
Mcl-1 in MKN45 Cells
To gain insight into the mechanism of apoptosis induction of
CDDP, we analyzed the expression of the pro-survival BCL2-
like proteins (Bcl-XL and Mcl-1), the pro-apoptotic factors
and BH3-only members: Bak, Bax, Bid, and Bad. We observed
downregulation of Mcl1 expression in MKN45 cells (almost 70%)
but not in AGS cells after 9 h of exposure to CDDP (Figure 2A).
By contrast, the expression of the pro-apoptotic proteins Bid and
Bad strongly increases from 9 to 24 h after treatment in MKN45
cells, whilst no effect was observed in AGS cells. No differences
were found in the other Bcl-2 member studied (Supplementary
Figure 2C).
Mcl-1 degradation is controlled by JNK and p38 MAPKs
thus, we analyzed their activation. Surprisingly, CDDP slightly
activated the stress kinases JNK and p38 only in MKN45 cells
but none in AGS cells (Figure 2B). In addition, we analyzed the
DUSP1 levels, the main phosphatase responsible of inactivation
of the three MAPKs. Our data indicated overexpression of
DUSP1 in AGS cells, which clearly explains the lack of JNK or
p38 activation in this type of cell line (Figure 2B). We observed
the phosphorylation of ERK kinases equally in both cell lines,
typically produce by cisplatin. To verify the role of p38 and
JNK activity on Mcl-1, we used the pharmacological inhibitors
SB203580 and JNK Inhibitor II for p38 and JNK, respectively.
As a control for the activity of these inhibitors, we analyzed the
phosphorylation of specific targets for these kinases, such as ATF2
and c-Jun (Supplementary Figure 2D). Our results indicated
that p38 inhibition blocked Mcl-1 degradation in MKN45 cells
(Figure 2C), but not by JNK inhibition.
These results strongly suggest that CDDP induces apoptosis in
MKN45 cells due to Mcl-1 degradation, in a process that depends
on p38 activity and upon the upregulation of Bid and Bad.
DNA Damage Repair and Impair in
Gastric Cancer Cells Treated With CDDP
The ability of CDDP to reach and react with the DNA is
ascribed to its anticancer activity. We tested then, the amount
of CDDP-adducts formed in AGS and MKN45 quantifying the
fluorescence intensity of the nuclei by using a specific antibody,
which recognizes CDDP-adducts. In both cell lines, we found
the nuclear intensity increased after 3 h of CDDP treatment
FIGURE 2 | Intrinsic apoptosis pathway by CDDP is mediated by Mcl-1 in
MKN45 cells. (A) Bcl-2 protein family members were detected by western blot
in AGS and MKN45 cells treated with CDDP (10 µg/ml) at the indicated
periods of time. Mcl-1, Bid, and Bad were detected by using specific
antibodies. (B) Cells were treated as in panel (A). ERK, JNK, p38
(phosphorylated and total forms), and DUSP1 expression were detected by
using specific antibodies. (C) AGS and MKN45 cells were pretreated during
30 min with 10 µM JNK Inhibitor II or p38 inhibitor (SB203580) before CDDP
treatment. Mcl-1 was detected by western blot at the indicated times after
treatment. α-Tubulin was used as loading control. WB images are
representative of the results obtained in three different experiments made in
the same conditions.
compared with the control (Figure 3A and Supplementary
Figure 3). In order to get more evidences from the damage
caused by cisplatin in our previous experiment; we measured the
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FIGURE 3 | DNA repair is impaired in MKN45 cells. (A) Graph represents nuclear fluorescent intensity of DNA adducts formed after treating AGS and MKN45 with
CDDP (10 µg/ml). Control cells (white bars) were untreated, or treated CDDP (black bars) for 3 h. DNA adducts were detected by using anti-(Pt-DNA) antibody.
(B) Subcellular distribution of CDDP in GC cells after 3 h of 10 µg/ml treatment. White bars represent the CDDP content in nucleus and black bars in cytoplasm.
Data are expressed as the mean values of the metal (nmol cisplatin) content in the nucleus or cytoplasm per million cells obtained in three different experiments.
(C) AGS and MKN45 cells were treated as in panel (A), and they were allowed to recover in normal media for 1 h before harvesting. γ-H2AX foci were detected by
Immunofluorescence, using DAPI to stain nuclear DNA. Graphs represent the percentage of nucleus within less than 15, between 15 and 50 and more than 50
γ-H2AX/nuclei for each condition. (D) Graphs represent the mean tail moment (TM) measured in at least 50 cells per duplicated in each condition after CDDP
treatment (10 µg/ml). Tables present the percentage of residual damage (RD) after the repair period. ∗∗∗p < 0.001.
platinum content into the nucleus and cytoplasm by ICP-mass
spectrometry. AGS and MKN45 cells were incubated with
cisplatin for 3 h and the nuclear fraction was separated from the
cytoplasmic fraction, and measured by ICP-MS (Figure 3B). The
platinum content in both fractions is much lower in the AGS cell
line than in the MKN45. Within these values, it is worth noticing
that, in both cell lines, the platinum content is almost as high in
the nucleus as in the cytoplasm, which also correlates with the
early time of measurement (3 h). Overall, these values proved that
the damage detected in the fluorescence experiment is caused by
the platinum binding.
We also analyzed the double-strands breaks generated by
CDDP in these cells, quantifying the number of DNA damage foci
per cell using antibodies against γ-H2AXSer139. Our data showed
that the number of foci per cell increased significantly 3 h after
CDDP treatment, on a range of 16 to 50 foci per nuclei. The DNA
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FIGURE 4 | CDDP selectively increased NER proteins in GC cells. (A) AGS and MKN45 cells were treated with 10 µg/ml CDDP and harvested at the indicated times.
RT-qPCR was used to quantify the mRNA levels of XPA, XPC, XPF, XPG, and ERCC1 by using specific primers (see section “Materials and Methods”). The graphs
represent the relative levels of each gene using 11CT referred to the levels on a control no tumorigenic cell line HACAT, and using GAPDH as endogenous control.
(B) XPC, XPD, XPA, and ERCC1 protein levels were detected by western blot in AGS and MKN45 cells after CDDP (10 µg/ml) treatment at the indicated times.
α-Tubulin was used as a loading control. (C) XPA levels in AGS and MKN45 cells after 6 h of CDDP treatment (10 µg/ml) in the presence of caffeine (80 mM) and
transfected with ATRWT or ATRDN plasmids. Arrow in XPA band indicates the non-processed protein. (D) Nuclear and cytoplasmic localization of XPC, XPD, and XPA
proteins were detected by western blot in AGS and MKN45 cells after 6 h of CDDP treatment (10 µg/ml) and cellular fractioning (C, Cytoplasm; N, Nuclei). α-Tubulin
was used as cytoplasmic protein loading control and lamin B1 was used as nuclear protein control. The experiments were repeated three times with similar results.
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FIGURE 5 | Hypothetical model to sensitize GC. DNA damage caused by CDDP leads to activation of NER, XPC is already in the nucleus and proteins XPA and XPD
translocate to the nucleus to repair the lesion. Resistant cells repair properly the DNA and survive, however, if repair is not efficient, the mitochondrial apoptosis
pathway is induced by Mcl-1 degradation and Bid and Bad induction. Option 1 (red circle) proposes the inhibition of XP proteins, and option 2 (green circle)
proposes the use of BH3 only mimetics.
damage foci numbers, after withdrawal of cisplatin, decreased in
AGS (range> 50 foci/nuclei) and kept increasing in MKN45 cells
(Figure 3C).
Next, we performed a comet assay to evaluate the repair rate
in these cells after CDDP treatment. Tail moment data showed
that AGS cells were able to repair CDDP adducts within 1 h; by
contrast, MKN45 cells needed at least 3 h to remove the damage.
Accordingly, the percentage of Residual Damage (% RD) reached
7.93 ± 1.4 in AGS versus 36.54 ± 3.5 in MKN45 cells after 3 h of
repair (Figure 3D). These results strongly suggest that AGS cells
repair CDDP induced DNA lesions more efficiently than MKN45
cells.
Nuclear Excision Repair Proteins
Expression After CDDP Treatment in
AGS and MKN45 Cells
The damage produced by cisplatin in the GC cells is generally
repair by NER system. We analyzed this pathway quantifying the
mRNA levels of different NER factors by RT-qPCR (Figure 4A).
Our results showed that the expression of the XPA and the
XPF is equally induced in both cell lines, in addition, no
major differences were observed in basal levels of the mRNAs.
Moreover, XPC highly increases after cisplatin treatment in
AGS, but this effect is not shown in MKN45. Lastly, XPG
and ERCC1 stayed the same with a slight increase at 24 h.
(Figure 4A). We also quantify a homologous recombination
repair (HRR) system, with no additional changes and the data
from BRCA1 and Rad51 have been collected in Supplementary
Figure 4. Next, we verified this NER system pathway by WB
analysis of the protein expression levels. We observed a clear
induction of XPC and ERCC1 expression (Figure 4B) from 12
to 24 h of treatment in both cell lines being slightly lower in
MKN45. Interestingly, we observed a modified pattern of the XPA
expression (Figure 4B) showing some extra-bands indicative of
post-transductional modifications (Figure 4C). ATR is known to
increase NER activity by phosphorylating and stabilizing XPA
in response to DNA damage (Lee et al., 2014). In order to
determine the effect of ATR or ATM kinases over XPA, we treated
MKN45 cells with caffeine in the presence and in the absence
of CDDP. Our results showed that pretreatment with caffeine
reduce the mobility shift of XPA, which points to changes in the
phosphorylated state of this protein (Figure 4C). To verify such
phosphorylation, AGS and MKN45 cells were transfected with
ATRWT or ATRDN expression vectors, and consistently with our
previous data, the shift of XPA in response to CDDP decreased
by expressing ATR dominant negative plasmid (Figure 4C).
With these data in hand, we can tell that DNA repair factors
are controlled differently between both cell lines in response to
CDDP.
We even gain more insight about the repair mechanism
examining XPA, XPC, and XPD localization. Subcellular
fractionation and WB analysis revealed that XPC in Nucleus was
highly expressed in AGS cells (Figure 4D); however, the amount
of XPC in MKN45 cells was considerably reduced, following
our previous results with RT-qPCR and WB. Although XPD is
restricted in the nucleus in both cell lines, we observed after
cisplatin treatment a low XPD increase in AGS cells and none
in MKN45. Finally, we observed that XPA, the key rate-limiting
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factor for NER (Kang et al., 2011), was translocated from the
cytosol into the nucleus after DNA damage induced by CDDP in
AGS cells. Interestingly, we did not find relocalization of XPA in
MKN45 cells where this factor remains localized in the cytoplasm
after CDDP treatment (Figure 4D).
DISCUSSION
In this manuscript, we seek to predict CDDP response in GC cells.
It is known that CDDP-induces apoptosis by a general pathway
in normal cells, however, cancer cells show specific particularities
leading, in some cases, to avoid the cell death. CDDP binds to
the DNA and induces bulky lesions which are mainly repaired by
NER mechanism and if the cells are not able to repair the damage
they end dying by apoptosis induction (Florea and Busselberg,
2011). Resistance mechanisms to CDDP avoids or decreases the
efficiency to treatment, so some efforts have been done in order
to find combined therapy using target pathways related with
resistance (Galluzzi et al., 2012).
We described here, that CDDP induces apoptotic cell
death in CDDP-sensitive GC cells (MKN45), through both
downregulation of the anti-apoptotic protein Mcl-1, and
induction of the pro-apoptotic BH3-only proteins Bad and Bid.
Our findings are in agreement with recent reports revealing
that suppression of the FoxM1/Mcl-1 pathway impairs cell
viability and thus increases sensitivity to CDDP in GC cells
(Li et al., 2016). Mcl-1 promotes cell transformation, cancer
survival, and resistance to chemotherapy, and selective Mcl-1
inhibitors competitively engage its binding groove, mimicking
the structural mechanism of action of native sensitizer BH3-
only proteins (Rezaei Araghi et al., 2018). Our data suggest that
CDDP mainly uses the Bad-dependent apoptotic pathway in GC.
Moreover, those markers are essential for caspase 9/3 activation
that finally produces cell death. And this Apoptotic induction
is observed as a consequence of cisplatin response in MKN45
and it is not observed in AGS. These data reinforce the need
to identify specific Bcl-2-family proteins as targets for treatment
improvement. The development of compounds mimicking the
function of BH3-only proteins is an emerging area of research.
Thus, many inhibitors had been developed in the last decade,
together with clinical trials (still ongoing) to study their effects
in combination with chemotherapy (Delbridge et al., 2016).
Chemoresistance is a major problem that leads to treatment
failure and death in GC patients. Among the various
chemoresistance mechanisms, overexpression of drug-resistance
proteins including drug transporter and DNA repairing systems,
are important defense mechanisms of cancer cells against
chemotherapeutic drugs. We have found that the less amount
of CDDP in the nucleus in resistant cells than in sensitive
cells, and the amount directly correlates with DNA damage
amount. One possible mechanism is that sensitive cells have
overexpression of proteins involved in the CDDP transport,
but our preliminary results do not confirm this hypothesis
(data not shown). Drug eﬄux transporters, including P-gp
(MDR1) and MRP1, are capable of reducing the intracellular
drug concentration. The resistance to 5-FU and irinotecan due
to the MRP associated cellular eﬄux processes has also been
reported (Suzuki et al., 2001).
The other mechanism must be related to DNA repair
mechanism. Our results point to this fact, as AGS cells
showed a competent DNA repair but MKN45 cells showed an
inefficient DNA repair. The NER system involves more than 30
protein–protein interactions and removes DNA adducts caused
by platinum-based chemotherapy (Jung and Lippard, 2007). XPC
is a DNA-damage-recognition gene active at the early stage of
DNA repair. In the present study, we study the expression levels
of genes involved in NER in GC cancer cells. This analysis
revealed that expression of XPC mRNA after CDDP treatment
significantly increased in AGS cells compared with MKN45
meaning that it may be a potential target for chemotherapy of
GC. This observation is in agreement data reported for CRC
cells (Zhang et al., 2018). XPD and XPA are important proteins
(helicase and recognition, respectively) within the NER pathway.
Our results show that the expression and translocation of XPD
and XPA to the nucleus in MKN45 cells is impaired. The
importance of this result must be related with ERCC1 which is
overexpressed in cancer cells. The XPA–ERCC1 complex seems to
be one of the most promising targets in this pathway. In fact, the
only known cellular function for XPA is to recruit ERCC1 to the
damaged point. These results open up two new lines of research:
(a) for the discovery of new NER inhibitors aimed at improving
the efficacy of current platinum-based therapy by modulating the
XPA–ERCC1 interaction (Gentile et al., 2016) and (b) for the
mechanism studies of XPA and XPD downregulation in MKN45
cells as a predictor of CDDP efficacy.
To summarize, we propose a model to sensitize GC cells in
those cases showing resistance to the drug based on the data
obtained in AGS and MKN cell lines (see Figure 5 for details).
The first option of this model embrace targeting the DNA repair
pathways (XPC, XPD, and XPA) surmounting CDDP resistance
in GC cells. The second option will be mimicking the BH3-only
proteins.
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